THREE-YEAR OUTCOME OF PEDIATRIC DACRYOCYSTORHINOSTOMY FOR TREATMENT OF CONGENITAL NASOLACRIMAL DUCT OBSTRUCTION
Egyptian Journal of Clinical Ophthalmology · 2018
DOI: 10.21608/ejco.2018.163050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Egyptian Journal of Clinical Ophthalmology, 2018. Verfasst von Abozaid und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Purpose: to retrospectively compare the success rates of external and endoscopicdacryocystorhinostomy (DCR) surgery performed for congenital nasolacrimal duct obstruction.
Methods
79 patients with congenital nasolacrimal duct obstruction that had either externalDCR (41, group 1) or endoscopic DCR (38, group 2) and completed 3 year duration aftersurgery were included in this study.
Results
38 patients in group 1 (92.7%) and 30 patients ingroup 2 (78.9%) showed success of surgery after 3 years of surgery, defining success as reliefof symptoms plus endoscopic visualization of the patent stoma (p value 0.079). Conclusion:Although the endoscopic approach of pediatric DCR has the advantages of the lack of skinincision, the preservation of the pump mechanism and the ability to address other nasalpathologies at the time of surgery, the external approach looks more successful on the long run.
Zitieren
APA
Abozaid, M., Abdelmonem, & M. (2018). THREE-YEAR OUTCOME OF PEDIATRIC DACRYOCYSTORHINOSTOMY FOR TREATMENT OF CONGENITAL NASOLACRIMAL DUCT OBSTRUCTION. Egyptian Journal of Clinical Ophthalmology. https://doi.org/10.21608/ejco.2018.163050
Vancouver
Abozaid, M., Abdelmonem, M.. THREE-YEAR OUTCOME OF PEDIATRIC DACRYOCYSTORHINOSTOMY FOR TREATMENT OF CONGENITAL NASOLACRIMAL DUCT OBSTRUCTION. Egyptian Journal of Clinical Ophthalmology. 2018. doi:10.21608/ejco.2018.163050
BibTeX
@article{Abozaid2018,
author = {Abozaid and M. and Abdelmonem and M.},
title = {THREE-YEAR OUTCOME OF PEDIATRIC DACRYOCYSTORHINOSTOMY FOR TREATMENT OF CONGENITAL NASOLACRIMAL DUCT OBSTRUCTION},
journal = {Egyptian Journal of Clinical Ophthalmology},
year = {2018},
doi = {10.21608/ejco.2018.163050}
}
EUVIMED